Iovance Biotherapeutics, Inc. (IOVA)
8.715
+0.10
(+1.10%)
USD |
NASDAQ |
Sep 03, 16:00
8.83
+0.12
(+1.32%)
After-Hours: 18:26
Iovance Biotherapeutics Research and Development Expense (TTM) : 267.71M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 267.71M |
| March 31, 2026 | 288.23M |
| December 31, 2025 | 302.62M |
| September 30, 2025 | 303.64M |
| June 30, 2025 | 296.71M |
| March 31, 2025 | 279.43M |
| December 31, 2024 | 282.34M |
| September 30, 2024 | 297.58M |
| June 30, 2024 | 316.86M |
| March 31, 2024 | 341.13M |
| December 31, 2023 | 344.08M |
| September 30, 2023 | 337.18M |
| June 30, 2023 | 322.16M |
| March 31, 2023 | 309.22M |
| December 31, 2022 | 294.78M |
| September 30, 2022 | 289.82M |
| June 30, 2022 | 282.68M |
| March 31, 2022 | 271.39M |
| December 31, 2021 | 259.04M |
| September 30, 2021 | 235.87M |
| June 30, 2021 | 213.57M |
| March 31, 2021 | 200.72M |
| December 31, 2020 | 201.73M |
| September 30, 2020 | 203.51M |
| June 30, 2020 | 202.05M |
| Date | Value |
|---|---|
| March 31, 2020 | 192.07M |
| December 31, 2019 | 166.02M |
| September 30, 2019 | 139.20M |
| June 30, 2019 | 125.57M |
| March 31, 2019 | 110.82M |
| December 31, 2018 | 99.83M |
| September 30, 2018 | 93.11M |
| June 30, 2018 | 82.91M |
| March 31, 2018 | 78.01M |
| December 31, 2017 | 74.72M |
| September 30, 2017 | 64.93M |
| June 30, 2017 | 55.66M |
| March 31, 2017 | 40.47M |
| December 31, 2016 | 28.04M |
| September 30, 2016 | 22.24M |
| June 30, 2016 | 18.74M |
| March 31, 2016 | 18.34M |
| December 31, 2015 | 16.16M |
| September 30, 2015 | 12.74M |
| June 30, 2015 | 8.107M |
| March 31, 2015 | 4.413M |
| December 31, 2014 | 2.705M |
| September 30, 2014 | 1.577M |
| June 30, 2014 | 1.473M |
| March 31, 2014 | 1.362M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Amgen, Inc. | 7.638B |
| Halozyme Therapeutics, Inc. | 102.37M |
| Neurocrine Biosciences, Inc. | 1.131B |
| AVITA Medical, Inc. | 20.15M |
| Editas Medicine, Inc. | 82.53M |